Is Ozempic Made From Lizard Venom?

Short answer: no. Semaglutide — the molecule sold as Ozempic and Wegovy — is not made from lizard venom. It was built in a lab from the human hormone GLP-1. But the reason anyone thought to build it at all traces back to a venomous lizard in the Arizona desert, and that part of the story is completely true.

It's one of those facts that sounds like an internet rumour and turns out to be real — just not in the way it usually gets told.

Here's what actually happened.

The lizard that doesn't eat

The Gila monster (Heloderma suspectum) is a heavy, black-and-orange lizard native to the American southwest and northern Mexico. It's one of the few venomous lizards in the world, and it has an unusual way of living: it may eat only a handful of large meals in an entire year.

That's a serious metabolic problem. Go months between meals and your digestive machinery has to switch almost entirely off, then come roaring back the moment food arrives. The Gila monster manages this without its blood sugar swinging wildly in either direction.

In the late 1980s, that puzzle caught the attention of a researcher named John Eng, an endocrinologist at the Veterans Administration Medical Center in the Bronx.

A hospital researcher with a hunch

Eng had developed his own assay for finding hormone-like peptides. He turned it on Gila monster venom — venom being, biologically speaking, a rich soup of peptides that do dramatic things to bodies.

In 1992 he and his colleagues published what they found: a 39-amino-acid peptide they named exendin-4. It shared roughly half its sequence with a human hormone called GLP-1 — glucagon-like peptide-1 — and, crucially, it did the same job. It bound the same receptor. It prompted the pancreas to release insulin, and only when glucose was actually elevated.

Your own body makes GLP-1. Your gut releases it when you eat. It is part of the normal, everyday machinery that keeps blood sugar in range — and, incidentally, one of the reasons fibre-rich meals behave so differently in the body than refined ones.

But human GLP-1 has a design flaw, at least from a drug developer's point of view. An enzyme called DPP-4 chews it up almost immediately. Its working life in the bloodstream is on the order of a couple of minutes.

Exendin-4 was different. The lizard peptide resisted that enzyme. It kept working for hours.

Nobody wanted it

This is the part of the story that tends to get skipped.

Eng had a peptide that mimicked a human blood-sugar hormone and lasted hours instead of minutes. For roughly three years, he could not persuade a single pharmaceutical company to take it seriously. A diabetes treatment derived from lizard venom sounded, to the industry of the early 1990s, faintly ridiculous.

In 1996 a small biotech called Amylin Pharmaceuticals finally licensed the patent. The synthetic version of exendin-4 was named exenatide. The US Food and Drug Administration approved it on 28 April 2005 under the brand name Byetta — the first GLP-1 receptor agonist ever brought to market.

Thirteen years from lizard to pharmacy.

So where does Ozempic actually come from?

Here's the correction that matters, because it's the bit almost every viral version gets wrong.

Exenatide is the venom-derived one. It is synthetic exendin-4 — the Gila monster peptide, made in a factory instead of a salivary gland.

Semaglutide is not. When Novo Nordisk's chemists set out to build a once-weekly GLP-1 drug, they didn't start from the lizard. They started from human GLP-1 and engineered it directly: two amino acid swaps to blunt the DPP-4 problem, plus a long fatty-acid chain attached to the peptide so it clings to albumin — a protein already circulating in your blood — and gets released slowly. The result is about 94% identical to the human hormone.

So the honest answer to "is Ozempic made from lizard venom" is: no, but its family tree starts there. Exendin-4 is the reason the entire GLP-1 drug class exists. It proved the concept. Semaglutide is a later, separately engineered branch of a tree the lizard planted.

Same lineage. Different molecule.

The pattern, again

If this shape feels familiar, it should. It's the same arc as metformin and goat's rue: nature turns up something with real pharmacology, and it takes decades of careful chemistry to turn that raw find into something safe, precise and usable in humans.

In both cases the useful thing was never the source itself. Nobody should chew goat's rue, and — this ought to go without saying, but the internet is what it is — nobody should go anywhere near a Gila monster. The value was in what the source revealed, and in the forty or fifty years of unglamorous laboratory work that followed.

It's also a good corrective to the reflex that "natural" and "synthetic" are opposites with moral weight attached. Exenatide is a synthetic copy of a wild animal's venom peptide. Semaglutide is a synthetic near-copy of a hormone your own gut makes several times a day. Neither of those facts, on its own, tells you anything about whether a drug is safe or appropriate for a given person. That's what evidence and a prescribing clinician are for.

The same reflex is why the supplement aisle keeps selling berberine as "nature's Ozempic" — a comparison that survives exactly as long as nobody checks what either molecule actually does.

What this article is not

This is a history and pharmacology piece. It is deliberately not a guide to taking GLP-1 medication.

GLP-1 receptor agonists are prescription-only drugs with real effects, real side effects, real contraindications, and a rapidly moving evidence base. Whether one is appropriate for anyone in particular is a conversation for that person and their doctor, and nothing here should be read as encouragement or discouragement either way.

What the story is good for is calibration. The next time something in this space sounds too strange to be true, it's worth checking — because sometimes an obscure hospital researcher really did find the future of metabolic medicine in a lizard nobody was paying attention to, and spent three years being told it was silly.

Calmly, Mr Blood Sugar.